Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib extension study in adults with chronic spontaneous urticaria
2024-510818-33-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Time to first composite event during randomized withdrawal period. Planned start Jan 2023; status: authorised.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-510818-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510818-33-00.